These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12709334)

  • 1. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG; Bhavnani SM; Jones RN
    Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms.
    Reese AM; Frei CR; Burgess DS
    Int J Antimicrob Agents; 2005 Aug; 26(2):114-9. PubMed ID: 16029947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
    VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of piperacillin-tazobactam against Klebsiella pneumoniae clinical isolates, producers or not of extended spectrum beta-lactamases].
    Alarcón T; de la Obra P; López-Hernandez S; de las Cuevas C; López-Brea M
    Rev Esp Quimioter; 1999 Sep; 12(3):229-33. PubMed ID: 10878513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
    Sader HS; Hsiung A; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):341-4. PubMed ID: 17141461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
    Vanscoy B; Mendes RE; McCauley J; Bhavnani SM; Bulik CC; Okusanya OO; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
    Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
    Leleu G; Kitzis MD; Vallois JM; Gutmann L; Decazes JM
    Antimicrob Agents Chemother; 1994 Feb; 38(2):195-9. PubMed ID: 8192442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
    Muller AE; De Winter BCM; Koch BCP
    J Antimicrob Chemother; 2024 May; 79(5):1093-1100. PubMed ID: 38507250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.